RxDoctor Payments Data

Lisa Ellis, MD

Infectious Disease · Austin, TXNPI 1497774020

Payments from drug & device makers

$1,922in general payments, 2019–2025

Across 94 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$651
  • Octapharma USA, Inc.$338
  • Insmed, Inc.$240
  • Merck$239
  • Gilead$162
  • Melinta Therapeutics, LLC$77
  • plus $215 from 7 others

What the payments were for

  • Food & beverage$1,922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,922 in reported general payments places this provider in the 65th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$213,394
Medicare patients
83
Services billed
7,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala185$830,839
DovatoDolutegravir Sodium/Lamivudine104$307,996
TriumeqAbacavir/Dolutegravir/Lamivudi74$277,651
JulucaDolutegravir/Rilpivirine59$199,084
OdefseyEmtricitab/Rilpiviri/Tenof Ala47$170,655
GenvoyaElviteg/Cob/Emtri/Tenof Alafen39$147,799
TivicayDolutegravir Sodium45$102,687
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf18$96,554
DescovyEmtricitabine/Tenofov Alafenam36$74,879
EdurantRilpivirine Hcl18$28,367
PrezcobixDarunavir/Cobicistat11$25,506
IsentressRaltegravir Potassium12$23,273
VemlidyTenofovir Alafenamide12$17,395
Fosfomycin Tromethamine13$4,912
AbacavirAbacavir Sulfate27$4,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$162$1,070,912272 claims
Viiv Healthcare CompanyDovato, Triumeq, Juluca, Tivicay$651$887,419282 claims
MerckIsentress$239$23,27312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →